SXShumeng Xue

Shumeng Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shumeng Xue has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Haoxiang Xu

    Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China

    2 shared publications
  • Yanyan He

    Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China

    2 shared publications
  • Chong Zhang

    Department of Dermatology, Plastic Surgery Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Lu Pei

    Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China

    1 shared publication
  • Qian Ye

    Department of Dermatology, Plastic Surgery Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    1 shared publication
  • Yi Zhang

    Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China

    1 shared publication

Latest Publications

  • Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling

    by Shumeng Xue, Yuanxing Shen, Chong Zhang, Qian Ye, Yi Zhang, Haoxiang Xu, Yanyan He

    Cutaneous squamous cell carcinoma (cSCC) is among the most common epithelial malignancies. Although cSCC arising in long‐standing acne inversa (AI) lesions is rare, it is a severe and clinically important complication of AI. Approximately one‐third of patients with AI harbour loss‐of‐function mutations in NCSTN . Whether NCSTN loss contributes to cSCC development remains unclear. To address this, we first examined its expression pattern in cSCC tissues. Interestingly, NCSTN expression was significantly decreased in cSCC tissues by immunohistochemistry (IHC) and Western blotting. Furthermore, loss of NCSTN promoted cSCC cell proliferation and migration in vitro and tumour growth in vivo. Proteomic analysis revealed that NCSTN deficiency promoted cell proliferation through activation of the MAPK/ERK signalling pathway, accompanied by reduced CLDN3 expression and alterations in cell‐adhesion‐related pathways. To validate the functional relevance of this signalling axis in vivo, we treated NCSTN‐knockdown tumour‐bearing mice with the ERK inhibitor SCH772984, which effectively suppressed tumour growth. Collectively, these findings demonstrate that loss of NCSTN drives cSCC progression through activation of MAPK/ERK signalling, and identify ERK signalling as a potential therapeutic vulnerability in NCSTN‐deficient cSCC.

  • Progress of Biologics and Small Molecule Drugs in the Treatment of Hidradenitis Suppurativa

    by Shumeng Xue, Yanyan He, Lu Pei, Haoxiang Xu

    Hidradenitis suppurativa (HS) is a chronic, debilitating, inflammatory skin disease that is challenging to treat. In recent years, biologic therapies and small‐molecule drugs have been used to improve the treatment landscape of moderate‐to‐severe HS. Biologics, including anti‐tumor necrosis factor‐α agents and interleukin inhibitors, target specific cytokines or cell‐surface receptors involved in the immunopathogenesis of HS. These therapies have shown efficacy in reducing inflammation, pain, and the formation of abscesses and fistulas, as well as in improving patients' quality of life. Small‐molecule drugs offer advantages such as oral administration, potentially different mechanisms of action, targeting of intracellular signaling pathways, and modulation of the immune response. Recent studies have focused on optimizing the use of these drugs, understanding their long‐term effects, and exploring combination therapies. This review summarizes progress in the application of biologics and small‐molecule drugs for the treatment of HS.